BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION (BARI

旁路血管成形术血运重建研究（巴里）是一项 协作、随机、多中心临床试验，旨在评估 经皮冠状动脉腔内成形术相对疗效 （PTCA）和冠状动脉旁路移植术（CABG）的患者， 需要侵入性治疗，并且冠状动脉解剖结构适合于 procedure. 这项研究需要七年时间完成，包括 方案制定和完善分阶段进行，为期一年， 患者招募，患者随访4年， 关闭临床单位、数据协调中心和放射学 实验室 所有接受冠状动脉造影的患者， 因严重或不稳定型心绞痛而合作的临床单位 有或无心肌梗死病史者，将被要求 参加巴里登记处。 所有符合条件的患者， 主治医生的同意，并满足待确定的纳入 和试验的排除标准，将随机接受治疗， 做了PTCA或CABG 这些患者将接受一段时间的随访， 不少于4年，使用死亡作为主要终点， 次要终点心肌梗死、充血性心力衰竭和 复发性心绞痛进行比较。

The Bypass Angioplasty Revascularization Investigation (BARI) is a collaborative, randomized, multicenter clinical trial designed to assess the relative efficacy of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) surgery in patients who require invasive therapy and have coronary anatomy suitable for either procedure. This study will require seven years for completion including phases of one year for protocol development and refinement, two years for patient recruitment, four years for patient follow-up and one year for close-out of the clinical units, data coordinating center and radiographic laboratory. All patients undergoing coronary arteriography at collaborating clinical units because of severe or unstable angina pectoris with or without antecedent myocardial infarction, will be asked to participate in the BARI registry. All patients who qualify, have their attending physician's consent, and satisfy the to be determined inclusion and exclusion criteria of the trial, will be randomized for therapy either with PTCA or CABG. These patients will then be followed for a period of not less than four years utilizing a primary end-point of death and secondary end-points of myocardial infarction, congestive heart failure and recurrent angina pectoris to compare these two groups.